Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 8/20 | 0.37 |
| ▸ | HTR2C | P28335 | 8/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22320234 | 0.82 | HTR2A (0.52) | HTR2AHTR2CCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL20876081 | 0.76 | HTR2C (0.49) | HTR2AHTR2C | |
| SCHEMBL20876078 | 0.76 | HTR2C (0.49) | HTR2AHTR2C | |
| SCHEMBL22320203 | 0.76 | HTR2A (0.49) | HTR2AHTR2C | |
| SCHEMBL22320222 | 0.74 | HTR2A (0.37) | HTR2AHTR2CCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL22320217 | 0.73 | HTR2A (0.33) | HTR2AHTR2C | |
| SCHEMBL3135537 | 0.72 | PRKCI (0.44) | HTR2AHTR2CCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL24143095 | 0.71 | HTR2C (0.63) | HTR2AHTR2CCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL20876045 | 0.70 | HTR2A (0.49) | HTR2AHTR2C | |
| SCHEMBL20876060 | 0.70 | SLC6A2 (0.40) | HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11629138-B2 | Microbiocidal picolinamide derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2023-04-18 | — | — | US | disclosed |
| EP-3692029-B1 | MICROBIOCIDAL PICOLINAMIDE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2023-04-12 | — | — | EP | disclosed |
| US-20200255400-A1 | Microbiocidal Picolinamide Derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2020-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200255400-A1 | Microbiocidal Picolinamide Derivatives | PRF1, CASP1, FPR1 | HTR2A 1946/4885HTR2C 2046/4885CYP1A2 305/4885 |
| US-11629138-B2 | Microbiocidal picolinamide derivatives | PRF1, CASP1, FPR1 | HTR2A 1946/4885HTR2C 2046/4885CYP1A2 305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.